ArticleJournal of the American Heart Association2023
NT-proBNP and All-Cause and Cardiovascular Mortality in US Adults: A Prospective Cohort Study.
Article in Journal of the American Heart Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Systematic review and meta-analysis of cardiovascular associated biomarkers in adults with asymptomatic autoimmune diseases.Frontiers in cardiovascular medicine · 2025Pooled it
- Using dapagliflozin to reduce symptoms in transthyretin cardiac amyloidosis: An n-of-1 trial series pilot study.PloS one · 2026Trial
- Prediction of cardiac arrest in patients with heart failure in Sweden: a registry study with development of a machine learning model.BMJ open · 2026Observational
- Proteomic health archetypes identified in disease-free adults enable risk assessment for diverse chronic diseases.Genome medicine · 2026Article
- Prevalence of Cardiovascular Disease Risk Factors and NT pro-BNP for Cardiovascular Disease Risk Prediction among Older People Living with HIV in Almaty, Kazakhstan.Research square · 2026Article
- Exploring Galectin‑3 as an Emerging Frontier in Biomarker Research for Clinical Trials Approaching Cardiovascular Diseases.ACS pharmacology & translational science · 2026Review
- The Efficacy and Safety of Enarodustat for the Treatment of Anemia in Hemodialysis-Dependent Chronic Kidney Disease Patients: A Phase 3, Multicenter, Randomized, Active-Comparator (Recombinant Human Erythropoietin), Open-Label Study - The ENARODIAL Study.American journal of nephrology · 2026Article
- NT-proBNP With Postoperative Complications and 2-Year Mortality Among Hip Fracture Patients: An Observational Cohort Study.Orthopaedic surgery · 2026Observational
- NT-proBNP and its association with autonomous aldosterone production in primary aldosteronism.Therapeutic advances in endocrinology and metabolism · 2026Article
- Evaluating early cardiology involvement and survival outcomes across NT-proBNP levels: An island-wide retrospective cohort study.European journal of heart failure · 2025Article
- Correlation of NT-proBNP With Duration of Hospital Stay in Patients With Heart Failure: A Retrospective Review.Cureus · 2025Article
- Improving stroke risk prediction in atrial fibrillation with circulating biomarkers: the CHAJournal of thrombosis and haemostasis : JTH · 2025Article
- Lower NT-proBNP plasma concentrations in Pacific peoples with heart failure.ESC heart failure · 2025Article
- NT-proBNP changes predict outcomes in elderly type 2 myocardial infarction patients.BMC geriatrics · 2025Article
- Tobacco Exposure and Markers of Myocardial Stress and Damage Among US Adults.The American journal of cardiology · 2025Article
- Machine learning-based prediction of elevated N terminal pro brain natriuretic peptide among US general population.ESC heart failure · 2025Article
- Delving into biomarkers and predictive modeling for CVD mortality: a 20-year cohort study.Scientific reports · 2025Article
- Short sleep duration in adults with congenital heart disease is associated with epicardial adipose tissue accumulation.Frontiers in psychiatry · 2025Article
- Association of cardiorenal biomarkers with mortality in metabolic syndrome patients: A prospective cohort study from NHANES.Chronic diseases and translational medicine · 2024Article
- Obesity Paradox and the Effect of NT-proBNP on All-Cause and Cause-Specific Mortality.Clinical cardiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
Background NT-proBNP (N-terminal pro-B-type natriuretic peptide) is strongly associated with mortality in patients with heart failure. Prior studies, primarily in middle-aged and older populations, have suggested that NT-proBNP has prognostic value in ambulatory adults. Methods and Results We conducted a prospective cohort analysis of adults, aged ≥20 years, in the nationally representative 1999 to 2004 National Health and Nutrition Examination Survey, to characterize the association of NT-proBNP with mortality in the general US adult population overall and by age, race and ethnicity, and body mass index. We used Cox regression to characterize associations of NT-proBNP with all-cause and cardiovascular disease (CVD) mortality through 2019, adjusting for demographics and cardiovascular risk factors. We included 10 645 individuals (mean age, 45.7 years; 50.8% women; 72.8% White adults; 8.5% with a self-reported history of CVD). There were 3155 deaths (1009 CVD-related) over a median 17.3 years of follow-up. Among individuals without prior CVD, elevated NT-proBNP (≥75th percentile [81.5 pg/mL] versus <25th percentile [20.5 pg/mL]) was associated with a significantly higher risk of all-cause (hazard ratio [HR], 1.67 [95% CI, 1.39-2.00]) and CVD mortality (HR, 2.87 [95% CI, 1.61-5.11]). Associations of NT-proBNP with all-cause and CVD mortality were generally similar across subgroups defined by age, sex, race and ethnicity, or body mass index (all
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.